Shares of Seres Therapeutics Inc. (NASDAQ:MCRB) were up 3.1% during trading on Monday . The stock traded as high as $34.17 and last traded at $33.76, with a volume of 158,514 shares. The stock had previously closed at $32.73.

Several analysts recently commented on MCRB shares. Zacks Investment Research lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 14th. Leerink Swann reissued a “buy” rating and set a $43.00 price target on shares of Seres Therapeutics in a report on Thursday, July 14th. FBR & Co initiated coverage on Seres Therapeutics in a report on Wednesday, March 30th. They set an “outperform” rating and a $40.00 price target for the company. Canaccord Genuity reissued a “buy” rating on shares of Seres Therapeutics in a report on Monday, May 16th. Finally, Cowen and Company initiated coverage on Seres Therapeutics in a report on Monday, June 6th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $43.86.

The firm’s market capitalization is $1.30 billion. The firm has a 50-day moving average price of $30.87 and a 200-day moving average price of $28.06.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.02. The firm earned $2.71 million during the quarter, compared to analysts’ expectations of $1.25 million. On average, equities research analysts forecast that Seres Therapeutics Inc. will post ($1.81) EPS for the current year.

In related news, CEO Roger Pomerantz sold 8,507 shares of the firm’s stock in a transaction on Friday, May 6th. The stock was sold at an average price of $24.31, for a total value of $206,805.17. Following the completion of the transaction, the chief executive officer now owns 31,234 shares in the company, valued at approximately $759,298.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Eric D. Shaff sold 4,533 shares of the firm’s stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $29.54, for a total value of $133,904.82. Following the completion of the transaction, the chief financial officer now owns 4,533 shares of the company’s stock, valued at approximately $133,904.82. The disclosure for this sale can be found here.

A number of institutional investors have recently modified their holdings of the company. ProShare Advisors LLC purchased a new position in shares of Seres Therapeutics during the fourth quarter worth about $1,146,000. Morgan Stanley raised its position in shares of Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock worth $1,185,000 after buying an additional 23,381 shares during the period. Finally, Jennison Associates LLC raised its position in shares of Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock worth $13,999,000 after buying an additional 7,259 shares during the period.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.